Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B‐cell lymphoma

Abstract

It has been suggested that mean platelet volume (MPV) is associated with the risk of venous thromboembolism (VTE) and increased mortality in patients with cancer. We evaluated the association of MPV with VTE and mortality in patients treated for diffuse large B-cell lymphoma (DLBCL). Retrospective analyses were performed on 184 adult patients (median age 59, 55% men), of whom 141 were newly diagnosed, and 43 had relapse/refractory DLBCL. During the observation period (median 499 days), 39 (21.2%) patients developed VTE. Thirty-nine patients died of various causes. In univariate analysis, only the MPV and the treatment line were associated with the occurrence of VTE. In multivariate analysis, MPV ≤10th percentile (odd ratio 1.81; 95% confidence interval 1.06-3.11, p = 0.03) and salvage therapy (odd ratio 2.46; 95% confidence interval 1.66-3.65, p < 0.001) remained significant factors for developing VTE. Other patient-related factors-age, gender, disease-related factors-stage, the International Prognostic Index score, DLBCL subclassification (the germinal centre type and the activated B-cell type), Ki-67 index and VTE risk assessment model failed to be prognostic for VTE. In a Kaplan-Meier analysis, patients with MPV >10th percentile had statistically significantly longer VTE-free survival than patients with lower MPV. In multivariable Cox regression analysis, MPV ≤10th percentile (hazard ratio 5.56, p < 0.001), male gender, age, Ki-67 index, high or high-intermediate International Prognostic Index and VTE development (hazard ratio 7.81, p = 0.029) all significantly correlated with the risk of mortality. The probability of survival was higher in patients with MPV >10th percentile. In conclusion, our results suggest that the pre-chemotherapy MPV value is a cheap and available parameter that may be a useful prognostic marker for a significant risk of VTE and inferior survival rates in patients with DLBCL.

Mean platelet volume predicts prognosis in patients with diffuse large B‐cell lymphoma

“…This study showed that the baseline low MPV was associated with decreased OS and PFS in patients with DLBCL in patients who receive a rituximab‐based chemotherapy, which supports the findings of previous studies …”

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma

“…However, it is unclear if thrombocytopenia per se favors HCC or is just a marker of more severe liver disease [24]. Furthermore, a lower mean platelet volume (MPV) was found to be an independent predictor of a reduced OS in patients with various cancer entities (excluding HCC) [26][27][28] with an especially pronounced effect in patients with localized solid tumors [29]. However, currently there is limited knowledge on the impact of platelet indices on tumor biology, outcomes, and survival in patients with established HCC [30].…”

Assessment of platelet reactivity after the anthracyclinebased chemotherapy via mean platelet volume: Does it act on anthracycline-induced cardiotoxicity?

“…In malignant tumors, platelets can lead to tumor progression and angiogenesis. High MPV is associated with uncontrolled and metastatic disease [24][25][26][27][28][29]. Therefore, in this study, we excluded the un-operated and metastatic patients due to a probable rise in MPV value.…”